Zanubrutinib Monotherapy in Relapsed/Refractory Central Nervous System Lymphoma
Status:
Not yet recruiting
Trial end date:
2025-07-01
Target enrollment:
Participant gender:
Summary
Zanubrutinib is a novel BTK inhibitor with proven activity in patients with various B-cell
lymphomas addicted to the B-cell receptor signaling pathway.